Loading...
•
Dec 31, 2020
Marinus Pharmaceuticals Q4 2020 Earnings Report
Marinus Pharmaceuticals reported fourth quarter 2020 financial results and provided a business update.
Key Takeaways
Marinus Pharmaceuticals reported a net loss of $17.5 million for the fourth quarter of 2020, with research and development expenses increasing to $13.0 million and general and administrative expenses increasing to $6 million. The company ended the year with $140.0 million in cash, cash equivalents and investments.
Marinus remains on track to submit a new drug application to the FDA for ganaxolone in CDKL5 Deficiency Disorder.
Active enrollment continues in the Phase 3 RSE trial.
Oral programs are advancing and expanding.
The company raised $70 million in December and ended the year with $140 million of cash on hand.
Forward Guidance
Marinus projects spend in the range of $18 to $20 million per quarter in 2021, offset by approximately $2 to $3 million per quarter from BARDA in 2021. This spend could increase in 3Q with the initiation of the TSC trial and ongoing expenses associated with the RAISE trial.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...